Changes in albuminuria predict mortality and morbidity in patients with vascular disease
about
Interplay of vitamin D, erythropoiesis, and the renin-angiotensin systemThe endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyPodocytes degrade endocytosed albumin primarily in lysosomesPredictive properties of plasma amino acid profile for cardiovascular disease in patients with type 2 diabetes.Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in Spain: PERCEDIME2 studyAssociation of high blood pressure with renal insufficiency: role of albuminuria, from NHANES, 1999-2006.Cumulative systolic BP and changes in urine albumin-to-creatinine ratios in nondiabetic participants of the multi-ethnic study of atherosclerosisEndocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death.Predictors of progression in albuminuria in the general population: results from the PREVEND cohort.The clinical status and survival in elderly dialysis: example of the oldest region of France.Active vitamin D treatment for reduction of residual proteinuria: a systematic review.Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray.Urinary immunoglobulin G to albumin ratio and N-Acetyl-Beta-D-Glucosaminidase as early predictors of therapeutic response in ANCA-associated glomerulonephritis.The predictive value of albuminuria for renal and nonrenal natural deaths over 14 years follow-up in a remote aboriginal communityRisk Prediction for Early CKD in Type 2 Diabetes.Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD.Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppressionProteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentrePredictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes.Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study.Global cardiovascular risk assessment in the management of primary hypertension: the role of the kidneyProgression of glomerular filtration rate reduction determined in conscious Dahl salt-sensitive hypertensive rats.Association of a reduction in central obesity and phosphorus intake with changes in urinary albumin excretion: the PREMIER studyA randomized trial of dietary sodium restriction in CKDAssociations between proteinuria and cardiovascular risk factors among hypertensive patients in Andkhoy, Afghanistan.Individualization of antihypertensive drug treatment.Effect of remote ischaemic conditioning on contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind placebo-controlled trial.Survival of chronic hemodialysis patients over 80 years of ageCurrent challenges in the clinical management of hypertension.Microalbuminuria as surrogate endpoint in therapeutic trials.Cardiovascular disease in chronic kidney disease: untying the Gordian knot.Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.Medical management and strategies to prevent coronary artery disease in patients with type 2 diabetes mellitus.Renal sympathetic denervation: applications in hypertension and beyond.Chronic kidney disease induced dysfunction of high density lipoprotein.Assessment of target organ damage in the evaluation and follow-up of hypertensive patients: where do we stand?Renal denervation--implications for chronic kidney disease.
P2860
Q26822500-2BDE0CA7-3A1D-443F-B88B-0382FBD80A3EQ28237978-4A4402A5-34EF-41C4-BB7F-A6D9CE5A1FF2Q33748757-DE48149E-565D-4C51-B55E-96F6C5397DABQ33817483-681ADBB9-6DE8-4F06-A3FF-914283981FA0Q34272651-1B570626-B288-43AE-BCF4-13B7D4B44CB4Q34339595-3C860A82-0F99-4633-9B7F-30362379D0DDQ34455151-53CA9FA7-6F74-40DA-ADEB-A8BD99FCE612Q34575711-0291EF47-6883-4A61-8CF6-AB4108E4E2D1Q34749180-B1438339-A9F7-4601-8845-1BE6941FDB81Q34783006-AAECB72C-E57E-40FF-82D8-1D7B8C7D9737Q34912750-07FBBAF4-D85A-4B38-B126-B8F1A3C861EFQ34926825-73C1C588-AA54-4FDF-B1AD-0181B8A568D1Q35021685-F15803AA-F70B-401D-9655-1059EE28ED7FQ35069739-05E69B0C-30D4-4D47-BD80-6364DE7E5632Q35452988-51EFB2BD-5F92-42DE-91C6-2AFE851B6EBBQ35691583-E8EB993B-4937-4792-85E7-A024D68E282FQ36417881-566C0BB7-12ED-4B53-A8F5-273EC5267E80Q36469066-242DE0FC-FCAB-4A1C-A5E6-7E99360B768FQ36670632-5F620C9D-FE75-4D01-881A-07843458F1EBQ36782780-DA90FDE0-FA8A-4226-B589-B133029D6A20Q36801566-2C76C98F-B968-45DD-B822-AFEBFE5118FDQ36851491-591848C6-FFFD-4B9E-AE1E-E08290729AF5Q37012488-93DAD9FE-6583-4FCC-92D5-E220DE54968CQ37100961-E5486790-77C7-488C-B195-F6C70734724DQ37251235-24D3F776-A5DF-4ECE-98F5-4A34398BCD0EQ37258125-7BE5FDC4-4B76-4802-A910-A5B706C560F7Q37340221-FE89BE00-4AC1-477A-B5CC-54A5118EA1B5Q37507414-75CA8B87-0590-46DC-86F2-428E29040BE1Q37577140-704502C9-F5A6-4573-B55E-3622175D9B6EQ37608257-39657BC4-A1F9-4B2A-AD68-B0BE50596B31Q37721841-80B3C799-4C76-4436-A9BE-BB172C21ABB4Q37949514-31045480-69F7-4E2E-B78C-9351488B4527Q38008566-BEDC0434-D1A4-4138-9C29-16AFC83E07CBQ38025185-61F1DBF7-6DB0-4F67-B46F-829FB39FF986Q38055501-1594CF11-5BAC-43B6-A443-FBFB2BE636ECQ38079914-3A38D2EF-4967-4892-8FF7-A04E44262B60Q38115114-1405BDBE-CEF2-4C1F-89AE-E8259C9F3D57Q38135683-910439BD-5AC1-47C9-A7C3-1885AD45B816Q38148620-2B9D4A77-FA19-44F7-AE53-6743013081FEQ38204682-905C9D36-3449-430C-8E45-5182BEB80997
P2860
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
@ast
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
@en
type
label
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
@ast
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
@en
prefLabel
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
@ast
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
@en
P2093
P2860
P356
P1476
Changes in albuminuria predict mortality and morbidity in patients with vascular disease
@en
P2093
Helmut Schumacher
Johannes F E Mann
Matthew McQueen
Michael A Weber
ONTARGET Investigators
Roland E Schmieder
P2860
P304
P356
10.1681/ASN.2010091001
P577
2011-06-30T00:00:00Z